Aardvark Therapeutics (NASDAQ:AARD) Receives Neutral Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research note released on Monday,Benzinga reports. They currently have a $6.00 target price on the stock.

Other analysts also recently issued reports about the company. Weiss Ratings upgraded Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. BTIG Research cut Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. B. Riley Financial lowered their price objective on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, Morgan Stanley reiterated an “underweight” rating and set a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $16.30.

Aardvark Therapeutics Stock Down 5.6%

AARD opened at $5.53 on Monday. Aardvark Therapeutics has a 52-week low of $3.35 and a 52-week high of $17.94. The company has a 50 day moving average of $4.82 and a two-hundred day moving average of $7.47. The company has a market cap of $121.00 million, a P/E ratio of -1.72 and a beta of 3.93.

Aardvark Therapeutics (NASDAQ:AARD) last issued its earnings results on Thursday, May 7th. The company reported ($0.99) EPS for the quarter. Research analysts anticipate that Aardvark Therapeutics will post -3.46 earnings per share for the current year.

Hedge Funds Weigh In On Aardvark Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Diadema Partners LP acquired a new stake in shares of Aardvark Therapeutics during the 4th quarter valued at approximately $208,000. Walleye Capital LLC bought a new position in Aardvark Therapeutics during the fourth quarter worth $211,000. Wells Fargo & Company MN boosted its holdings in Aardvark Therapeutics by 259.5% in the fourth quarter. Wells Fargo & Company MN now owns 14,080 shares of the company’s stock worth $185,000 after purchasing an additional 10,163 shares during the period. MetLife Investment Management LLC acquired a new position in Aardvark Therapeutics in the fourth quarter worth $102,000. Finally, Bank of America Corp DE increased its stake in Aardvark Therapeutics by 72.9% during the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after purchasing an additional 3,369 shares during the last quarter.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.